Syngene International Q2 FY27 Earnings: Key Metrics

Results are scheduled for October 27

Syngene International Ltd. is scheduled to announce its second-quarter FY27 financial results on October 27, 2026. The contract research and manufacturing company had last reported quarterly results for the period ended June 30, 2026, on July 29. Attention will be on revenue growth, operating profitability and the impact of lower sales of the veterinary drug Librela. Brokerages tracking the company expect profit to face pressure from product-specific demand trends and losses at newer facilities. Their revenue estimates for the September quarter indicate a broadly flat performance compared with the year-ago period. The scheduled results will provide the company’s first reported financial update for the September 2026 quarter. Investors will also look for management commentary on biologics operations and facility ramp-up costs.

Brokerages see a wide range for net profit

Three brokerage estimates cited ahead of the results place Syngene’s Q2 FY27 net profit between ₹466 million and ₹765 million. The highest estimate, from YES Securities (India), implies 16% year-on-year growth. The lowest estimate, from 360 ONE Capital Market, indicates that profit could decline by almost 30% from a year earlier. The range reflects differing assumptions about revenue mix, the biologics business and costs linked to new facilities. The available estimates do not point to a uniform view on the company’s bottom-line performance. Still, they broadly identify profitability as the key issue for the quarter. Syngene will detail the actual performance when it releases its September-quarter numbers.

Revenue estimates indicate limited year-on-year movement

Brokerages estimate September-quarter net sales at ₹7.92 billion to ₹8.46 billion. YES Securities has the highest sales estimate and expects marginal year-on-year growth. 360 ONE Capital has the lowest estimate and forecasts a decline of more than 4% year on year. Syngene had reported net sales of ₹8.30 billion in the comparable year-ago quarter, according to the brokerage preview. These estimates support the view that revenue may remain broadly flat on an annual basis. The final reported revenue can vary from brokerage estimates because companies may present revenue from operations and consolidated net revenue differently. The results release will clarify the reported measure and the drivers of quarterly movement.

EBITDA may decline as costs remain elevated

Estimated EBITDA for the September quarter ranges from ₹1.70 billion to ₹2.01 billion. YES Securities has the highest estimate, while Kotak Securities has the lowest. Kotak expects EBITDA to fall 20% year on year but rise 20% sequentially. Brokerages expect losses at new facilities and lower Librela sales to weigh on operating earnings. The estimated EBITDA margin is expected to contract by 250 basis points year on year to 20.7%. Margin movement matters because it captures the effect of revenue mix and operating costs beyond the sales headline. Any update on utilisation at recently added facilities will therefore be relevant to the market’s assessment of the quarter.

Librela and new facilities are key variables

The brokerages cited loss of sales of Librela as a factor likely to affect Syngene’s September-quarter earnings. Librela is a veterinary drug, and lower sales have been identified as a drag on the company’s expected performance. The same previews also point to expected losses at new facilities. New manufacturing and biologics capacity can carry pre-operating and ramp-up expenses before utilisation reaches a level that supports profitability. This dynamic was visible in earlier disclosures related to the company’s US biologics facility. The current quarter’s results may show whether these costs continue to influence margins. No outcome should be assumed before the company reports its numbers and management commentary.

Q2 FY26 provides the immediate comparison

In Q2 FY26, Syngene reported consolidated net profit of ₹671.0 million, down 37% year on year. Revenue was ₹9.26 billion, up 3.9% from the same quarter a year earlier. Revenue from operations in that period was ₹9.11 billion, compared with ₹8.91 billion in Q2 FY25, while reported EBITDA was ₹2.15 billion. EBITDA declined 18% year on year, and the margin stood at 23.2%. The company had said research services revenue helped offset an anticipated inventory correction in biologics manufacturing. It also maintained its annual revenue guidance for FY26 at that time. The different revenue figures reported across sources reflect the distinction between revenue from operations and wider net revenue measures.

Full-year FY26 showed profit pressure

For full-year 2026, Syngene reported revenue of ₹37.4 billion, up 2.6% from FY25. Net income declined 36% year on year to ₹3.17 billion. Earnings per share fell to ₹7.87 from ₹12.35 in FY25. The annual figures show that revenue growth did not translate into comparable growth in net income during the period. This context makes the September-quarter margin and profit data particularly important. Investors will be assessing whether revenue growth in research services can offset pressure in other business areas. The company’s guidance and comments on demand will also help place the quarterly figures in a broader context.

Earlier disclosures highlighted biologics costs

In its Q2 FY26 disclosures, Syngene said it had accumulated ₹165 million in pre-operating costs for its US biologics facility. It also reported a write-off of ₹277 million, or ₹202 million after tax, related to foreign-exchange fluctuations. The company had announced plans to expand its biologics facility in Bengaluru and said it had secured a significant contract for a global phase III clinical trial. These developments indicate continued investment and activity across its research and manufacturing operations. But the September-quarter preview suggests that near-term costs at new facilities remain relevant to earnings. The results will show how these operating factors have moved since the prior reported period.

What the market will track in the announcement

The October 27 announcement will be watched for actual revenue, EBITDA, margin and net-profit figures against the brokerage ranges. Market participants will also look for details on Librela-related sales, biologics demand and the performance of research services. Updates on losses or pre-operating costs at new facilities will be relevant to the operating-margin discussion. Syngene’s prior Q2 commentary maintained annual revenue guidance for FY26, but the supplied information does not provide FY27 guidance. As a result, any fresh outlook provided with the Q2 FY27 results will be an important new disclosure. The scheduled conference call for Q2 FY27 results may provide additional context after the financial release. Until then, the available estimates indicate a quarter defined by steady sales expectations and uncertain profitability.